HCV Treatment Failure in the Era of DAAs

Hassany, Mohamed; Elsharkawy, Aisha

doi:10.5772/67149

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, none of the baseline factors showed significant association with treatment failure in the subgroup of patients with severe renal impairment except for serum bilirubin. Some clinical trials on DAAs showed mildly better response in treatment naive patients than those who previously failed treatment with Peg‐IFN‐RBV . Advanced fibrosis stage also affects the response rates to DAAs with a wide variable SVR results in cirrhotic patients ranging between 33% and 100% SVR rates …”

Section: Discussionmentioning

confidence: 99%

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Eletreby

El‐Serafy

Anees

et al. 2019

Liver International

Self Cite

View full text Add to dashboard Cite

Background and Aims This study aimed to assess the safety and efficacy of sofosbuvir (SOF)‐based regimens in patients with moderate to severe renal impairment; a subject which has been questioned by many investigators with conflicting results. Methods This is a real‐life multicentre retrospective cohort study on 4944 chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) (eGFR <60 mL/min/1.73 m2) who received SOF‐based therapy in specialized treatment centres affiliated to the National Committee for the Control of Viral Hepatitis in Egypt. The efficacy and safety of SOF‐based regimens was assessed. Results Week 12 virological response rates were 97.5%, 96.7%, 85.7% and 80% in the total cohort, patients with eGFR <30 mL/min/1.73 m2, patients with associated hepatic decompensation and patients on dialysis respectively. Various treatment regimens did not statistically affect the response rates. Treatment experience, cirrhosis and diabetes were predictors of treatment failure on multivariate analysis. Serious adverse events occurred in 0.1% of cases. Forty patients (0.8%) discontinued treatment. Conclusion Sofosbuvir‐based regimens are effective and safe for treating patients with chronic HCV and moderate to severe CKD, and in those with associated hepatic decompensation.

show abstract

Section: Discussionmentioning

confidence: 99%

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Eletreby

El‐Serafy

Anees

et al. 2019

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The most major factor leading to treatment failure is the development of viral resistance. Although this incident is rather rare, it nonetheless presents a difficult scenario [7,8] .…”

Section: Hcv Treatment Failurementioning

confidence: 94%

Management of Hepatitis C Treatment Failures Following Direct Acting Antiviral Therapy: Review Article

2024

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

“…Терапия ПППД демонстрирует устойчивый вирусологический ответ, в среднем >90 %, по сравнению с 40-50 % устойчивого вирусологического ответа при использовании интерферона и рибавирина при инфекции ВГС генотипов 1 и 4, 60-70 % при генотипах 5 и 6 и 80-90 % при генотипах 2 и 3. Доступность терапии ПППД расширяет возможность излечения от хронического гепатита С (ХГС) для различных групп пациентов, которые в эпоху интерферона не рассматривались для назначения терапии, например, пациенты с заболеваниями печени, аутоиммунными заболеваниями, почечной недостаточностью или пациенты после трансплантации органов [8].…”

Section: Introductionunclassified

Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region

Ekushov,

Totmenin,

Gotfrid

et al. 2024

Ûg Ross.: èkol. razvit.

View full text Add to dashboard Cite

To research the molecular genetic characteristics of the HCV population circulating among HIV‐infected residents of the Krasnoyarsk Territory, including analysis of resistance‐associated mutations to NS5A inhibitors. Total RNA was isolated from 94 blood plasma samples from HIV/HCVinfected residents of the region and the nucleotide sequences of the Core/E1 gene and NS5A gene regions were obtained and deciphered, which were used for genotyping and searching for resistance mutations.In the HCV samples studied, the circulation of five virus subtypes was recorded: 1b (47,9 %), 3a (37,2 %), 1a (10,6 %), 2a (3,2 %) and 2k (1,1 %). Phylogenetic analysis of HCVs revealed partial clustering within subtypes 1a and 3a on a territorial basis. HCV subtypes 1b, 2a and 2k were grouped with other HCVs previously isolated in Russia, Armenia and Kyrgyzstan. Among the HCVs studied, no clusters were found that were common to HIV‐infected individuals with the same route of infection. Among patients who had no experience of taking DAAs, HCV resistance mutations in the NS5A region were found in 42,3 % of cases for those infected with subtype 3a virus and in 75,6 % of cases for those infected with HCV subtype 1b.The analysis of the diversity and occurrence of mutations of HCV drug resistance to direct antiviral drugs is extremely important for the development of tactics for effective treatment of CHC. The high prevalence of polymorphic mutations that affect sensitivity to DAAs indicates the relevance of introducing HCV resistance analysis into clinical practice.

show abstract

HCV Treatment Failure in the Era of DAAs

Cited by 4 publications

References 23 publications

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Management of Hepatitis C Treatment Failures Following Direct Acting Antiviral Therapy: Review Article

Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region

Contact Info

Product

Resources

About